Join to View Full Profile
8136 Old Keene Mill RdSte A309Springfield, VA 22152
Phone+1 800-287-2829
Fax+1 703-726-2579
Dr. Uzel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
National Institutes of Health Clinical CenterFellowship, Allergy and Immunology, 1997 - 1999
Sinai Hospital of BaltimoreResidency, Pediatrics, 1994 - 1997
Ankara University FOMClass of 1991
Certifications & Licensure
MD State Medical License 2002 - 2025
VA State Medical License 2007 - 2022
IL State Medical License 2002 - 2008
Clinical Trials
- Genetic Analysis of Immune Disorders Start of enrollment: 1995 Jun 06
- Antibody Production in Immune Disorders Start of enrollment: 2002 Jun 13
- Safety and Efficacy of Abatacept for Treating Chronic Cytopenia in Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Haploinsufficiency Start of enrollment: 2023 Nov 30
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Inborn errors of immunity reveal molecular requirements for generation and maintenance of human CD4IL-9-expressing cells.Geetha Rao, Corinne D Mack, Tina Nguyen, Natalie Wong, Kathryn Payne
The Journal of Allergy and Clinical Immunology. 2025-04-01 - Correction: The intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency.Prabha Chandrasekaran, Máté Krausz, Yu Han, Noriko Mitsuiki, Annemarie Gabrysch
Microbiome. 2025-03-15 - 2 citationsThe intestinal microbiome and metabolome discern disease severity in cytotoxic T-lymphocyte-associated protein 4 deficiency.Prabha Chandrasekaran, Máté Krausz, Yu Han, Noriko Mitsuiki, Annemarie Gabrysch
Microbiome. 2025-02-11
Other
- Mendelian susceptibility to mycobacterial diseases (MSMD)Uzel G
http://www.uptodate.com/contents/mendelian-susceptibility-to-mycobacterial-diseases-msmd
UpToDate, Wolters Kluwer Health - 2012-09-19
Press Mentions
Pharming Group Announces Development Plans for Leniolisib for Additional Primary Immunodeficiencies (PIDs)December 17th, 2023
Grant Support
- Leniolisib for immunedysregulationNATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESPresent
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
